The KDM5D Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the KDM5D gene in the human NCI-H1703 lung squamous cell carcinoma line. This loss-of-function model enables investigation of KDM5D??s role in epigenetic regulation. The cells are produced through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited alleles that collectively ablate KDM5D function. This format avoids clonal selection limitations, providing a representative population for studying the overall impact of KDM5D ablation on cellular phenotypes and gene expression.
NCI-H1703 is a widely used non-small cell lung cancer (NSCLC) cell line derived from a squamous cell carcinoma. It retains key features of lung squamous cell carcinoma, including reliance on androgen receptor (AR) signaling and chromatin remodeling pathways. The line??s male (XY) origin permits study of Y-linked genes such as KDM5D in a somatic cancer context. NCI-H1703 cells are commonly employed in research on proliferation, apoptosis, migration, and drug response, and they express a full complement of histone modification machinery, making them an appropriate host for epigenetic manipulation.
KDM5D encodes a histone demethylase specific for H3K4me2/me3, repressing transcription of target genes. Its expression is regulated by androgens and the androgen receptor. The protein interacts with RB1, histone deacetylases, and the Polycomb complex, linking it to tumor suppressor and chromatin remodeling pathways. KDM5D knockout eliminates demethylase activity, leading to H3K4 hypermethylation at promoters of cell cycle and apoptosis genes, altering chromatin accessibility and gene expression. This disrupts the balance between H3K4 methyltransferases and demethylases, with implications for AR-driven transcriptional programs.
In NCI-H1703 lung squamous cell carcinoma cells, KDM5D knockout provides a platform to dissect Y chromosome-specific epigenetic regulation in cancer. Since KDM5D operates downstream of AR signaling and interacts with chromatin modifiers, its loss may affect proliferation, survival, and tumorigenicity. The polyclonal knockout population mirrors heterogeneous editing outcomes, enabling assessment of collective phenotypic consequences relevant to therapeutic ablation. This model is valuable for exploring how epigenetic alterations drive NSCLC and for studying the interplay between KDM5D and HDACs or Polycomb proteins in oncogenic gene expression.
Key applications include measuring global H3K4me3 changes via Western blotting, quantifying target gene expression by RT-qPCR, profiling promoter-specific H3K4me3 enrichment through ChIP-qPCR, and assessing functional impact with cell proliferation and migration assays. The cells support research on Y chromosome gene function in cancer, AR-driven transcriptional regulation, and epigenetic mechanisms of drug resistance, particularly to HDAC or AR inhibitors. They can also be used in screens for compounds that modulate H3K4 methylation status. For further inquiries, please contact Ascent Research.
